Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 5/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936090 | 0.86 | TP53 (0.35) | UTS2RKDM4EALDH1A1TACR2SLC6A3 | |
| SCHEMBL2410809 | 0.80 | KDM2B (0.40) | UTS2RTACR2CHRM2CHRM3KDM2B | |
| SCHEMBL2394311 | 0.80 | NOS3 (0.34) | KDM4E | |
| SCHEMBL1936313 | 0.80 | NOS3 (0.32) | KDM4E | |
| SCHEMBL1936591 | 0.79 | HRH3 (0.39) | UTS2ROPRK1CYP3A4CYP2D6TACR2 | |
| SCHEMBL1935943 | 0.79 | TP53 (0.38) | UTS2ROPRK1CYP3A4CYP2D6TACR2 | |
| SCHEMBL1936263 | 0.78 | CACNA2D1 (0.38) | CYP3A4KDM2B | |
| SCHEMBL1936572 | 0.78 | LMNA (0.42) | CYP3A4 | |
| SCHEMBL1936656 | 0.77 | HTR2A (0.34) | KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL1935963 | 0.76 | CACNA2D1 (0.32) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-09-01 | — | — | US | disclosed |
| EP-2331505-A2 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | UTS2R 2214/4885OPRK1 304/4885CYP3A4 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.